Retina

A look at what’s in the therapeutic delivery pipeline for these disorders.

Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

Further research is needed before dietary nitrate intake can be recommended as a therapy for age-related macular degeneration, according to the study authors.

Apellis has received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.

Prof Anat Loewenstein, Chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), comments on the significance of the US FDA approval of aflibercept for preterm infants with retinopathy.

Mild cases of retinopathy of prematurity may improve without treatment, but some cases require treatment to keep ROP from causing significant visual impairment and even blindness.

An interdisciplinary team at Duke University has developed a proof-of-concept machine learning model capable of detecting symptomatic Alzheimer disease using multimodal retinal imaging data.

The most promising recent interventional trials for investigational therapies in dry age-related macular degeneration are highlighted by the authors.

The delivery of lipid nanoparticle-based mRNA to the retina is encouraging, according to researchers.

Three recipients will each receive up to $10,000 toward their research on a 1-year project that can go toward additional training in specialty equipment or research methodologies.

Ultra-widefield imaging may be a promising technology for assessing larger areas of the retinal vasculature to uncover retinal changes in Alzheimer’s disease, according to investigators.

Ocular involvement in IBD is a rare extraintestinal manifestation, but may be critical because of its potential sight-threatening complications if not treated promptly and accurately, according to researchers.

The research team reported a few differences in patients that included a decreased mean vessel density at the deep vascular complex of the macula, a decreased mean subfoveal choroidal thickness, and an increase in the size of the foveal avascular zone.

Best-corrected visual acuity and minimum linear diameter before surgery may be indicators for anatomical success.

Resection techniques for choroidal tumours are based on modern vitreoretinal surgical techniques, which allow for the treatment of more challenging cases.

Findings may help pediatricians and ophthalmologists to determine the appropriate timing of examinations and treatment.

Pegcetacoplan is the only GA treatment to demonstrate increased effects over 24 months across a broad patient population.

Understanding vitreomacular interface diseases is key to treatment.

Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

A recent survey of retinal clinic patients reveals a lack of awareness of the risks and safety issues associated with stem cell therapies.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

The funding will give a boost to the development of the company's novel photo-crosslinked EyeLief, EyeLief-SD, and OcuLie biodegradable drug-delivery technologies.

Giving patients access to new treatments and information on changing their lifestyle habits could result in major steps towards minimising or even preventing geographic atrophy.